- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
ImmuneOnco Biopharmaceuticals Shanghai Inc (1541)
ImmuneOnco Biopharmaceuticals Shanghai Inc stock price live, this page displays HK 1541 stock exchange data. View the 1541 premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the ImmuneOnco Biopharmaceuticals Shanghai Inc real time stock price chart below.
What Is the ImmuneOnco Biopharmaceuticals Shanghai Inc Stock Price Today?
The ImmuneOnco Biopharmaceuticals Shanghai Inc stock price today is 6.25.
What Is the Stock Symbol for ImmuneOnco Biopharmaceuticals Shanghai Inc?
The stock symbol for ImmuneOnco Biopharmaceuticals Shanghai Inc is "1541."
What Stock Exchange Does ImmuneOnco Biopharmaceuticals Shanghai Inc Trade On?
ImmuneOnco Biopharmaceuticals Shanghai Inc is listed and trades on the Hong Kong stock exchange.
Is ImmuneOnco Biopharmaceuticals Shanghai Inc a Good Stock to Buy?
Determining whether ImmuneOnco Biopharmaceuticals Shanghai Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 1541 quote. (ISIN: CNE100006624)
What Is the ImmuneOnco Biopharmaceuticals Shanghai Inc Stock Price Today?
The ImmuneOnco Biopharmaceuticals Shanghai Inc stock price today is 6.25.
What Is the Stock Symbol for ImmuneOnco Biopharmaceuticals Shanghai Inc?
The stock symbol for ImmuneOnco Biopharmaceuticals Shanghai Inc is "1541."
What Stock Exchange Does ImmuneOnco Biopharmaceuticals Shanghai Inc Trade On?
ImmuneOnco Biopharmaceuticals Shanghai Inc is listed and trades on the Hong Kong stock exchange.
Is ImmuneOnco Biopharmaceuticals Shanghai Inc a Good Stock to Buy?
Determining whether ImmuneOnco Biopharmaceuticals Shanghai Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 1541 quote. (ISIN: CNE100006624)
Hong Kong
Currency in HKD
6.25
+0.02(+0.32%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
6.16
6.39
52 wk Range
3.21
22.00
1541 Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
6.166.39
52 wk Range
3.2122.00
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
1541 Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales decline in the current year
No news in this category
Looks like there are no results in this news category
ImmuneOnco Biopharmaceuticals Shanghai Inc Company Profile
ImmuneOnco Biopharmaceuticals (Shanghai) Inc., a biotechnology company, engages in the research and development of immuno-oncology therapies in the People’s Republic of China. Its core product candidate is IMM01, which is in Phase Ib/IIa clinical trial to evaluate the combination with bortezomib and dexamethasone for the treatment of multiple myeloma; Phase II clinical trial in combination with azacitidine for the first-line treatment of higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia; and Phase III clinical trial in combination with tislelizumab, targeting relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) patients who relapsed or progressed after the treatment of PD-1 inhibitors. It also develops IMM0306 that is in Phase Ib/IIa clinical trial for the treatment of R/R CD20-positive B-cell non-Hodgkin lymphoma (B-NHL); IMM2510, which is in Phase Ib/IIa clinical trial to treat R/R soft tissue sarcoma; IMM27M that in Phase I clinical trial to treat solid tumors; IMM2520, which is in Phase I clinical trial for solid tumors; IMM2902 that in Phase I clinical trial for the treatment of HER2-positive and low expressing solid tumors; and IMM47 for the treatment of advanced malignant and solid tumors, and R/R B-NHL. In addition, the company develops IMC-002 for treating autoimmune indications; IMC-001 for the treatment of atherosclerosis; IMM72; IMM7211b; IMM51, IMM38, IMM50, and IMM62 for solid tumors; and IMM40H for liquid/solid tumors. The company has license and collaboration agreement with Instil Bio, Inc. for the development of IMM2510 and IMM27M. ImmuneOnco Biopharmaceuticals (Shanghai) Inc. was incorporated in 2015 and is headquartered in Shanghai, China.
Compare 1541 to Peers and Sector
Metrics to compare | 1541 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship1541PeersSector | |
|---|---|---|---|---|
P/E Ratio | −7.5x | −1.3x | −0.5x | |
PEG Ratio | −0.37 | 0.03 | 0.00 | |
Price/Book | 3.5x | 4.2x | 2.6x | |
Price / LTM Sales | 29.9x | 9.7x | 2.9x | |
Upside (Analyst Target) | 161.9% | 67.2% | 56.4% | |
Fair Value Upside | Unlock | 8.8% | 9.3% | Unlock |
Earnings
Latest Release
Mar 25, 2025
EPS / Forecast
-0.39 / --
Revenue / Forecast
78.82M / --
FAQ
What Is the ImmuneOnco Biopharmaceuticals (1541) Stock Price Today?
The ImmuneOnco Biopharmaceuticals stock price today is 6.25
What Stock Exchange Does ImmuneOnco Biopharmaceuticals Trade On?
ImmuneOnco Biopharmaceuticals is listed and trades on the Hong Kong Stock Exchange stock exchange.
What Is the Stock Symbol for ImmuneOnco Biopharmaceuticals?
The stock symbol for ImmuneOnco Biopharmaceuticals is "1541."
What Is the ImmuneOnco Biopharmaceuticals Market Cap?
As of today, ImmuneOnco Biopharmaceuticals market cap is 2.54B.
What is ImmuneOnco Biopharmaceuticals Earnings Per Share?
The ImmuneOnco Biopharmaceuticals EPS is -0.84.
From a Technical Analysis Perspective, Is 1541 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.